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LETTER TO THE EDITOR

The underrecognized prothrombotic vascular disease of
COVID-19
We have read with interest “COVID-19-associated coagulopathy

around elevated markers of hypercoagulability, including D-dimer,

and thromboembolic disease: Commentary on an interim expert

tissue factor expression, fibrinogen levels, factor VIII levels,

guidance” recently provided by Cannegieter and Klok.1 This com-

short-activated partial thromboplastin time, platelet binding, and

mentary exemplifies the importance that venous thromboembolism

thrombin formation. 8 Based on well-defined clinical and laboratory

(VTE) and atheroembolism may be underrepresented and a cause

parameters, a proposal for staging COVID-19 coagulopathy may

for increased morbidity and mortality among coronavirus disease

provide treatment algorithms stratified into 3 stages.9 However,

2019 (COVID-19) patients. COVID-19 is mainly recognized as an

reports on acquired thrombophilias, such as antiphospholipid anti-

acute infectious disease caused by the severe acute respiratory

body syndrome, have been limited and should be considered among

syndrome coronavirus 2; however, COVID-19 is emerging as an un-

patients with COVID-19 in the right clinical context, especially

derrecognized hypercoagulable endothelial vascular disease that has

among those without severe coagulopathy or known VTE risk fac-

contributed to significant morbidity and mortality. Although similar

tors (eg, immobility, active cancer, chronic neurological disease with

thrombotic events have occurred during outbreaks of severe acute

leg paresis).10

2

respiratory syndrome (SARS), emerging data, reports, and commen-

To address these thrombotic concerns in COVID-19, provid-

tary of the prothrombotic complications (eg, VTE and arterial compli-

ers should obtain a detailed inquiry into constitutional or spe-

cations) in patients with COVID-19 is rapidly accumulating. Recently,

cific symptoms and consider certain laboratory and diagnostic

3

Cui and colleagues retrospectively reported a lower-extremity VTE

testing that might affect treatments and outcomes. Patients with

incidence of 25% (20/81) with a mortality of 40% (8/20) among the

COVID-19 who develop arterial thrombosis require a thorough

81 patients diagnosed with severe COVID-19 pneumonia. Klok and

evaluation for a vasculitis, systemic or local infections, trauma,

colleagues 4 reported a 13% mortality rate among 184 intensive care

dissection, vasospasm, atheroembolism (eg, artery-to-artery em-

units (ICU) patients infected with COVID-19, with 3.7% having ar-

bolism, VTE through patent foramen ovale), or vascular anomaly.

terial thrombotic events and 27% with VTEs confirmed by imaging

Furthermore, patients with COVID-19 should be considered for

despite the use of standard-dose thromboprophylaxis. Furthermore,

testing for heparin-induced thrombocytopenia, disseminated in-

Llitjos and colleagues5 reported a 69% incidence of VTE events

travascular coagulation, or for acquired thrombophilia, such as

among patients with COVID-19 in the ICU. Moreover, pulmonary

antiphospholipid antibodies (eg, lupus anticoagulant, anticardi-

embolism (PE) has been reported in 23% of COVID-19-positive ICU

olipin antibodies, anti-β2 glycoprotein-1 antibodies) in the right

patients while on thromboprophylaxis.5 Although the recent data

clinical context.

demonstrate a high incidence of thromboembolic complications, es-

Currently, there are no absolute indications for routine ac-

pecially VTE complications, in hospitalized patients with COVID-19

quired thrombophilia testing among patients with COVID-19.

in the ICU with respiratory failure, to date, the literature of VTE com-

The role of special coagulation testing for an acquired thrombo-

plications on medical wards or outpatients with COVID-19 remain

philia must be considered in the context of the clinical presenta-

sparse. Reports of strokes in the young and middle-aged have also

tion and should be done only if the results are likely to change

6

been increasing among patients with COVID-19. Similarly, large-ar-

medical management. Relative indications among patients with

tery cerebral thrombosis have been seen among individuals with

COVID-19 could include selected screening among those with

SARS caused by coronavirus in 2004.7 The mechanism underlying

an incident thrombotic event at a young age (eg, ≤40-45 years

morbidity related to thrombosis in patients with COVID-19 remains

for venous thrombosis, ≤50-55 years for arterial thrombosis), re-

unclear, but the importance of recognizing the thrombogenicity of

current thrombosis without risk factors, unprovoked thrombosis,

COVID-19 is imperative, preventable, and potentially lifesaving.

or thrombosis in unusual vascular territories (eg, cerebral vein,

Many of the emerging reports surrounding the potential causes
for thrombosis, demand ischemia, or microthrombosis have evolved

portal vein, hepatic vein, mesenteric vein or artery, renal vein or
artery).
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Acute thrombosis can transiently reduce the lev-
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pairing the interpretation of clot-based assays for a lupus
anticoagulant. Direct oral anticoagulants may cause false-
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activity. Direct leukocyte genomic DNA testing for the factor V
Leiden and prothrombin G20210A mutations is unaffected by an-
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ticoagulation therapy and can be performed at any time.
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The typical duration of anticoagulation therapy among patients
with thrombosis may not apply to all patients with COVID-19 or

REFERENCES

clinical situations and warrants further study. Until further research

1. Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and
thromboembolic disease: commentary on an interim expert guidance.
Res Pract Thromb Haemost. 2020. https://doi.org/10.1002/rth2.12350.
2. Lew TWK, Kwek T-K, Tai D, Earnest A, Loo S, Singh K, et al. Acute
respiratory distress syndrome in critically ill patients with severe
acute respiratory syndrome. JAMA. 2003;290:374–80.
3. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.
J Thromb Haemost. 2020;18:1421–1424.
4. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers
DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
5. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M,
Auvray M, et al. High incidence of venous thromboembolic events
in anticoagulated severe COVID-19 patients. J Thromb Haemost.
2020. https://doi.org/10.1111/jth.14869.
6. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh PI,
et al. Large-vessel stroke as a presenting feature of Covid-19 in the
young. N Engl J Med. 2020;382(20):e60.
7. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo
TT, et al. Large artery ischaemic stroke in severe acute respiratory
syndrome (SARS). J Neurol. 2004;251(10):1227–31.
8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
associated with poor prognosis in patients with novel coronavirus
pneumonia. J Thromb Haemost. 2020;18(4):844–7.
9. Thachil J, Cushman M, Srivastava A. A Proposal for Staging COVID19 Coagulopathy. Res Pract Thromb Haemost. 2020. https://doi.
org/10.1002/rth2.12372.
10. Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus
anticoagulant and abnormal coagulation tests in patients with
Covid-19. N Engl J Med. 2020:NEJMc2013656.
11. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M,
et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–64.
12. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux
H. Antithrombotic therapy for VTE disease: CHEST guideline and
expert panel report. Chest. 2016;149:315–52.

suggests otherwise, patients with COVID-19 with an acquired
thrombophilia and a first-lifetime VTE should be managed by existing
guidelines.12 Similarly, the risks and benefits of extended anticoagulation should be reassessed periodically because the risk of VTE
recurrence following an incident event is unknown among patients
with COVID-19, and the risk of anticoagulant-related bleeding also
may vary over time.
Providers need to have an increased vigilance against possible
thrombotic complications among patients with COVID-19 and appropriate laboratory and/or diagnostic testing should not be delayed
so that necessary therapeutic treatments may be given to reduce
and/or prevent significant morbidity and mortality.
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